1Bertram P,Willem R, Faiez Z. Eplerenone,a selective Aldosteone blcker, in patients with left ventricular dysfunction after myocardial infarction.New Eng J Med, 2003, 348 (14) :1309-1321.
2Masara Hayashi,Takayoshi Tsutamoto, Atsuyuki Wada. Immediate administration of mineralocorticoid receptor antagonist sporonolactone prevents post-infarct lefe ventricular remodeling associated with suppression of a Marker of Myocardial Collagen Synthesis
3Watanabe T. Endothelin in myocardial infarction. Nature, 1990,344:114.
4Sigurdsson A, Swedberg K. The role of neurohormonal activation in CHFand post MI. Am Heart J, 1996,132: 229-234.
5Bart CS, Lang CC, Hanson J. Effect of adding spironolactone to in ACE inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardial, 1995,120:893-901.
6Silvestre JS. Myocardial production of aldosterone and corticosterone in the rat. J Bio chem, 1998, 273:4883-4891.
7Brilla CG, Pick R,Tan LB, et al. Remodeling of the rat tight and left ventriculaes in ecperimental hypertension. Cire Res,1990, 67:1355-1364.
8Robert V. Differential regulation of matrix metalloproteinases associated with aging and hypertension in the rat heart. Lab Invest, 1997, 100:253-258.
9Wehling M. Aldosterone specific membranes receptors,rapid activation of the sodium-hydrogen exchanger and cardiovascular inplication. J Cardiovase Res, 1995, 29(2) :167-171.
10Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone trestment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteonism. J Mol Cell Cardiol, 1993, 25:563-575.
